7HD.F NEUCA S.A.
- Market cap
- EUR 677M
- P/E
- 14.9x
- P/B
- 2.68x
- ROE
- 19.5%
- Dividend yield
- 2.73%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7HD.F undervalued?
Graham number7HD.F trades 33.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NEUCA S.A. fundamental analysis
No fundamental analysis for NEUCA S.A. yet.
NEUCA S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NEUCA S.A.
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, …
Full company profileNEUCA S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NEUCA S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 9.86B | 11.2B | 11.8B | 12.6B | 13.6B | 14.3B |
| Gross Profit | 1.02B | 1.13B | 1.31B | 1.44B | 1.56B | 1.70B |
| Operating Income | 254M | 256M | 271M | 304M | 296M | 346M |
| EBITDA | - | 350M | 400M | 418M | 393M | 480M |
| Net Income | 151M | 137M | 146M | 154M | 156M | 218M |
| EPS | 35 | 32 | 33 | 34 | 35 | 48 |
| Balance Sheet | ||||||
| Total Assets | 4.06B | 4.76B | 5.18B | 5.51B | 6.24B | 6.23B |
| Total Liabilities | 3.17B | 3.82B | 4.12B | 4.10B | 4.97B | 4.90B |
| Shareholders' Equity | 844M | 883M | 990M | 1.14B | 1.06B | 1.12B |
| Cash & Short-term Investments | 64.6M | 208M | 105M | 110M | 138M | 92.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 300M | 336M | 288M | 63.2M | 549M | 283M |
| Capital Expenditure | 52.8M | 81.4M | 94.2M | 92.9M | 125M | 93.2M |
| Free Cash Flow | 247M | 254M | 194M | -29.7M | 424M | 190M |
| Ratios | ||||||
| ROE | 17.8% | 15.5% | 14.8% | 13.5% | 14.7% | 19.5% |
| ROA | 3.7% | 2.9% | 2.8% | 2.8% | 2.5% | 3.5% |
| Net Profit Margin | 1.5% | 1.2% | 1.2% | 1.2% | 1.1% | 1.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NEUCA S.A. dividends
- Dividend yield
- 2.73%
- Forward dividend
- 4.11 EUR
- Payout ratio
- 46.3%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | PLN 72.0M | 16 | 46.3% |
| 2024 | PLN 66.2M | 15 | 43.0% |
| 2023 | PLN 58.2M | 13 | 39.8% |
| 2022 | PLN 51.6M | 12 | 37.6% |
| 2021 | PLN 44.2M | 10 | 29.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NEUCA S.A.
- Insiders 60.55%
- Institutions 10.22%
- Public & others 29.23%
- Shares outstanding 4.52M
- Free float 1.61M
NEUCA S.A. company profile
- Company name
- NEUCA S.A.
- Ticker
- 7HD.F
- ISIN
- PLTRFRM00018
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Distribution
- Employees
- 5,004
- Fiscal year end
- December
- Address
- Forteczna 35-37, Torun, Poland, 87-100
- Phone
- 48 56 669 4000
- Website
- neuca.pl
About NEUCA S.A.
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brands. It also provides medical care services, including prevention, diagnostics, treatment, and complementary services; and financing services, such as insurance, subscriptions, occupational medicine, preventive and medicine programmes, FFS, NFZ, public, private, and corporate payer services. In addition, the company offers TPA services, remote consultations, in person visits, diagnostic tests, and occupational medicine services; operates a medical helpline and medical facilities; and offers medicine through apteline.pl, an e-commerce medical ordering site. Further, it engages in running clinical trials in the field of outsourcing clinical research and conducting clinical research centres; provision of insurance products, including health insurance products. Additionally, the company provides advertising and marketing services to pharmaceutical market entities; and logistics services for pharmaceutical manufacturers. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.
NEUCA S.A. management
5- Mr. Grzegorz DzikPresident of the Management Board
- Mr. Krzysztof MiszewskiVice President of Management Board for Operations
- Mr. Daniel WojtkiewiczVice President of the Management Board & Director of the Sales Division
- Ms. Julita CzyzewskaVice President of the Management Board for the Patient Area
- Mr. Roman DudzikVice President of the Management Board the Board of Directors for the IT Division